(MENAFN- GlobeNewsWire - Nasdaq)main-body-container" itemprop="articleBody">
FLORHAM PARK, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 10:00 a.m. ET.
Company management will also participate in one-on-one meetings during the virtual conference which runs from June 1-4, 2021.
To access the live webcast and archived recording of the presentation, visit the News & Events section of the Phathom website at . The recording will be available for 90 days following the event.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company's website at or follow the Company on social media: LinkedIn at and Twitter .
CONTACTS
Media Contact:
Nick Benedetto
1-877-742-8466
Investor Contact:
Todd Branning
1-877-742-8466
![]()
MENAFN25052021004107003653ID1102135756
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.